Venous thromboembolism in multiple myeloma: Current perspectives in pathogenesis
- 31 July 2010
- journal article
- review article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 46 (10), 1790-1799
- https://doi.org/10.1016/j.ejca.2010.03.007
Abstract
No abstract availableKeywords
This publication has 100 references indexed in Scilit:
- Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trialThe Lancet Oncology, 2009
- Epoetin-β treatment in patients with cancer chemotherapy-induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic eventsBritish Journal of Cancer, 2009
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple MyelomaNew England Journal of Medicine, 2008
- Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated AnemiaJAMA, 2008
- Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North AmericaNew England Journal of Medicine, 2007
- Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple MyelomaNew England Journal of Medicine, 2007
- Proteasome inhibitor bortezomib for the treatment of multiple myelomaLeukemia, 2006
- Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trialThe Lancet, 2006
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005
- Thalidomide as initial therapy for early-stage myelomaLeukemia, 2003